Business Wire

MINISTER-HAJJ-UMRAH

11.1.2023 13:04:35 CET | Business Wire | Press release

Share
Hajj Expo 2023 Kicks Off, Under the Patronage of Makkah Governor

H.R.H Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques and Governor of Makkah Region, and H.R.H Prince Faisal bin Salman bin Abdulaziz Al Saud, Governor, Madinah Province inaugurated the 2023 conference and exhibition on Hajj and Umrah ‘Hajj Expo’. Held in Jeddah, the second edition of Hajj Expo featured 81 speakers from public and private sectors, as well as high-level delegations of ministers of religious affairs, heads of Hajj missions and higher authorities from +57 countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005423/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

H.R.H Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques and Governor of Makkah Region touring the exhibition with H.E. Minister of Hajj and Umrah, Dr. Tawfiq bin Fawzan Al-Rabiah (Photo: AETOSWire)

H.E. Minister of Hajj and Umrah, Dr. Tawfiq bin Fawzan Al-Rabiah welcomed the esteemed guests, noting that Saudi Arabia’s top priority is to ensure that pilgrims can perform Hajj and Umrah safely and securely by enhancing the digital capabilities of services. “This is a historical commitment and an honor to be proud of for the Two Holy Mosques government,” he said.

Al-Rabiah reiterated the Ministry’s keenness to enrich the Hajj and Umrah experience by developing services and solutions and introducing enhanced regulations and procedures. He praised the commitment of relevant authorities and the early signing of Hajj agreements as ‘testament to the unrelenting keenness to provide better services to pilgrims and Umrah performers.’

The event witnessed several agreements and MoUs between key entities, notably the General Authority for Awqaf (GAA), the Saudi Conventions and Exhibitions General Authority (SCEGA), the King Salman Global Academy for Arabic Language (KSAA), the Saudi Standards, Metrology and Quality Organization (SASO) and the Media and Banking Awareness Committee for Saudi Banks. More than 57 Hajj service agreements were also signed, regarding Hajj pilgrim numbers, dedicated plans for the arrival of pilgrims, and health requirements and procedural instructions.

Hajj Expo discussed ways to enhance quality of Hajj services in 10 keynote sessions, 13 panel discussions and ‘Hajj Talks’, as well as 36 workshops and other events and activities: the Islamic exposition, the Hajj and Umrah Challenge Area, and the Startup Zone.

Hajj Expo aims at building an integrated and sustainable ecosystem of services and solutions to enhance the experience of pilgrims, anticipate future directions and establish opportunities for further collaborations, agreements, and local and international initiatives, while showcasing Saudi Arabia’s efforts to enhance the sustainable development of pilgrim services.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005423/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye